Education
About Us
Working with TipRanks
Follow Us
Nanobiotix SA (GB:0QAV)
LSE:0QAV
0QAV Stock Chart & Stats
€16.18
-€0.07(-2.36%)
At close: 4:00 PM EST
€16.18
-€0.07(-2.36%)
Day’s Range― - ―
52-Week Range€2.68 - €25.55
Previous CloseN/A
Volume19.00
Average Volume (3M)47.85K
Market Cap
€784.10M
Enterprise Value€218.02M
Total Cash (Recent Filing)€49.74M
Total Debt (Recent Filing)€50.90M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 18, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 15, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding47,943,150
10 Day Avg. Volume62,181
30 Day Avg. Volume47,854
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-2.17
Price to Sales (P/S)-12.30
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.00Price Target Upside35.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical DataNanobiotix presented clinical data updates showing JNJ-1900 can elicit anti-tumor activity both locally at the injected lesion and systemically.
Safety And ResponseJNJ-1900 demonstrates an acceptable safety profile and improved clinical response in a tumor agnostic manner.
Treatment EfficacyThe complete response of 46% in the study for esophageal cancer is impressive, suggesting JNJ-1900 plus chemotherapy could be a feasible alternative to surgery.
Bears Say
Nanobiotix News
0QAV FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest share price was €2.68 and its highest was €25.55 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €784.10M.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Nov 18, 2025 which is in 18 days.
How were Nanobiotix SA’s earnings last quarter?
Nanobiotix SA released its earnings results on Sep 30, 2025. The company reported -€0.11 earnings per share for the quarter, beating the consensus estimate of -€0.31 by €0.2.
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Nanobiotix SA dividends here
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 47,943,150 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Nanobiotix SA reported an EPS of -€0.11 in its last earnings report, beating expectations of -€0.31. Following the earnings report the stock price went down -3.929%.
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in GB:0QAV
Company Description
Nanobiotix SA
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
0QAV Stock 12 Month Forecast
Average Price Target
€22.00
▲(35.97% Upside)
Technical Analysis
Genfit
―
Innate Pharma SA
―
Abivax SA
―
DBV Technologies
―
OSE Immunotherapeutics SA
―
Options Prices
Currently, No data available
---